Why is Rapport Therapeutics stock sliding today?

Rapport Therapeutics (RAPP) priced offerings of $175M in common stock at $21/share, $25M in pre-funded warrants, and $150M in convertible notes due 2032. It also agreed to a $30M private placement. Proceeds will fund clinical trials, R&D, and operations through 2029. RAPP stock is down 15.32% to $23.32.

Rapport Therapeutics (RAPP) shares dropped 20% premarket Wednesday after announcing a $350M capital raise. The company offered $175M in common stock, $25M in pre-funded warrants, and $150M in convertible notes. Proceeds will fund clinical trials, R&D, and operations through 2029, with net proceeds estimated at $360.7M after expenses.

Rapport Therapeutics (RAPP) shares dropped 22% after raising $380M via stock, convertible notes, and private placement at $21/share, a 24% discount. The company aims to fund trials after positive bipolar mania data. It held $436.1M in cash at Q2-end, with increased cash burn. Upcoming milestones include an FDA meeting in Q1 2027 and Phase 3 trials in 2027.

Rapport Therapeutics (RAPP) shares dropped 24% premarket after pricing offerings totaling $365M, including $175M in common stock, $150M in convertible notes, and $30M in private stock placement.

Rapport Therapeutics Inc. (RAPP) raised $380M via a public offering of $175M in common stock at $21/share, $25M in pre-funded warrants, and $150M in convertible notes. The company also secured a $30M private placement. Proceeds will fund clinical trials and R&D. The offerings are expected to close by October 30, 2026.

Rapport Therapeutics (RAPP) raised $175M via common stock at $21.00, $25M via pre-funded warrants, and $150M via 2.25% convertible notes due 2032, plus a $30M private placement. The funds will support RAP-219 trials and pipeline development, with key data expected from FOCUS 1/2 and bipolar mania trials.